ADAP News and Press, Adaptimmune Therapeutics plc From 12/09/22

Summary ADAP has been in a sea of trouble, lately. Its rolling BLA of afamicel, to be started this quarter, is its immediate lifeline. I will continue watching the stock with interest. Just not going to buy now. Adaptimmune ( ADAP ), I noted previously, had been a ...

- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after a single dose of afami-cel - - Overall response rate in synovial sarcoma of 39% by independent review -consistent with previous data - -Media...

Penny Stocks To Buy According To 5 Wall Street Analysts Contrary to popular opinion, penny stocks aren’t just lottery tickets or no-name companies. This year, more than others, this has become a fact, especially considering the massive sell-off in the broader markets. Househo...

Mizuho has upgraded Adaptimmune Therapeutics ( NASDAQ: ADAP ) to buy from neutral saying there is now clarity on the regulatory strategy for TCR T-cell therapy afami-cel for solid tumors. The firm kept its price target at $9 (~333% upside based on Tuesday's close...

Shares of the anti-cancer cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having an unusually strong showing today. Specifically, the biotech's stock is up by a whopping 26.8% on sky-high volume as of 2:17 p.m. ET on Tuesday. What's fueling this double-digit ral...

Adaptimmune Therapeutics plc (ADAP) Q3 2022 Earnings Conference Call November 8, 2022 8:00 A.M. ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Elliot Norry - Chief Medical Officer Gavin Wood - Chief Fi...

Adaptimmune press release ( NASDAQ: ADAP ): Q3 GAAP EPS of -$0.04 beats by $0.22 . Revenue of $7M (+483.3% Y/Y) beats by $2.03M . The Company is deprioritizing non-core programs and is also undertaking a restructuring of the Company including a headcount reduct...

Adaptimmune Therapeutics ( NASDAQ: ADAP ) reported updated data from a phase 1 trial called SURPASS evaluating ADP-A2M4CD8 across multiple solid tumor indications. The company said objective response rate (ORR) increased to 52% (from 44% reported at ESMO...

Adaptimmune will focus on programs in MAGE-A4 and PRAME, two of the most validated T-Cell targets in solid tumors  Adaptimmune will initiate a rolling BLA submission for afami-cel for the treatment of synovial sarcoma in Q4 2022 with target for completion in mid-year 2023  ...

New responses in ovarian and urothelial cancers increase ORR to 52% from 44% in heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers after single dose of ADP-A2M4CD8  Across the entire ongoing Phase 1 SURPASS trial, the ORR has increased to 37%...